中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.013 seconds)

    RISK ASSESSMENT FOR ADVERSE DRUG REACTIONS
    1.
    发明申请
    RISK ASSESSMENT FOR ADVERSE DRUG REACTIONS 审中-公开
    不良药物反应的风险评估

    公开(公告)号：US20130330724A1

    公开(公告)日：2013-12-12

    申请号：US13966996

    申请日：2013-08-14

    Applicant: Academia Sinica

    Inventor： Yuan-Tsong Chen ,  Shuen-lu Hung ,  Wen-hung Chung ,  Jer-Yuarn Wu

    IPC: C12Q1/68

    CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/94

    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

    Abstract translation: 本发明提供了一种预测患者发展不良药物反应（特别是SJS或TEN）的风险的方法。 发现HLA-B等位基因HLA-B * 1502与由各种药物诱导的SJS / TEN相关。 与HLA-B * 1502的相关性对于卡马西平诱导的SJS / TEN是最显着的，其中所有测试的患者具有HLA-B * 1502等位基因。 另外HLA-B等位基因HLA-B * 5801与别嘌呤醇诱导的SJS / TEN特别相关。 特别是与第三等位基因HLA-B * 4601相关的皮肤反应较轻，如斑丘疹，多形性红斑，荨麻疹和固定药物爆发。 对于任何等位基因，位于特异性HLA-B单倍型的DRB1和HLA-A区之间的遗传标记（例如HLA标记，微卫星或单核苷酸多态性标记）也可用于测试。

    Risk assessment for adverse drug reactions
    4.
    发明授权
    Risk assessment for adverse drug reactions 有权
    不良药物反应的风险评估

    公开(公告)号：US09562268B2

    公开(公告)日：2017-02-07

    申请号：US13966996

    申请日：2013-08-14

    Applicant: Academia Sinica

    Inventor： Yuan-Tsong Chen ,  Shuen-lu Hung ,  Wen-hung Chung ,  Jer-Yuarn Wu

    IPC: C12Q1/68 ,  C12P19/34 ,  G01N33/94 ,  C12M1/34

    CPC classification number: C12Q1/6881 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/94

    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

    Abstract translation: 本发明提供了一种预测患者发展不良药物反应（特别是SJS或TEN）的风险的方法。 发现HLA-B等位基因HLA-B * 1502与由各种药物诱导的SJS / TEN相关。 与HLA-B * 1502的相关性对于卡马西平诱导的SJS / TEN是最显着的，其中所有测试的患者具有HLA-B * 1502等位基因。 另外HLA-B等位基因HLA-B * 5801与别嘌呤醇诱导的SJS / TEN特别相关。 特别是与第三等位基因HLA-B * 4601相关的皮肤反应较轻，如斑丘疹，多形性红斑，荨麻疹和固定药物爆发。 对于任何等位基因，位于特异性HLA-B单倍型的DRB1和HLA-A区之间的遗传标记（例如HLA标记，微卫星或单核苷酸多态性标记）也可用于测试。

Patent Agency Ranking